QURE News

CLASS ACTION REMINDER: Berger Montague Advises uniQure N.V. (NASDAQ: QURE) Investors to Inquire About a Securities Fraud Lawsuit by April 13, 2026

QURE Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in uniQure N.V. Securities Lawsuit -- The Gross Law Firm

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against uniQure N.V.

QURE SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that uniQure N.V. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit!

uniQure N.V. Securities Fraud Class Action Result of FDA Approval Delay and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

Pomerantz LLP Issues Alert Regarding Shareholder Class Action Involving uniQure N.V. – QURE

Class Action Filed Against uniQure N.V. (QURE) Seeking Recovery for Investors – Contact Levi & Korsinsky

QURE INVESTOR ALERT: uniQure Faces Securities Class Action Over AMT-130 Clinical Trial Design - Hagens Berman

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages uniQure N.V. Investors to Secure Counsel Before Important Deadline in Securities Class Action - QURE

Bronstein, Gewirtz & Grossman LLC Urges uniQure N.V. Investors to Act: Class Action Filed Alleging Investor Harm